Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Gastrointestinal Stromal Tumor

Completed

2

Start Date 08/01/2013

Age of Trial (yrs) 11.3

Gleevec-resistant

KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI)

Block KIT + Block blood vessel growth

Specifically GIST plus other cancers

CTKI258AUS26

Novartis

Novartis Pharmaceuticals 1-888-669-6682 Enrollment Call Center 1-855-744-6727

Oral

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET